Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: Aug 11, 2025
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2025.
Read more at globenewswire.com
